Who are LCP-tacrolimus QD + MMF QD then MMF QD's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): XR-tacrolimus QD + MMF BID, XR-tacrolimus QD + MMF BID then MMF QD.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lcp-tacrolimus-qd-mmf-qd-then-mmf-qd.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

LCP-tacrolimus QD + MMF QD then MMF QD — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LCP-tacrolimus QD + MMF QD then MMF QD (LCP-tacrolimus QD + MMF QD then MMF QD) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcineurin inhibitor + antimetabolite immunosuppressant combination. Area: Immunology / Transplantation.

marketed Calcineurin inhibitor + antimetabolite immunosuppressant combination Calcineurin (tacrolimus); inosine monophosphate dehydrogenase type II (MMF) Immunology / Transplantation Small molecule Live · refreshed every 30 min

Target snapshot

LCP-tacrolimus QD + MMF QD then MMF QD (LCP-tacrolimus QD + MMF QD then MMF QD) — University Hospital, Limoges. LCP-tacrolimus is a prolonged-release formulation of tacrolimus that suppresses T-cell activation and proliferation, combined with mycophenolate mofetil (MMF) which inhibits inosine monophosphate dehydrogenase to reduce lymphocyte proliferation, together providing dual immunosuppression.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
LCP-tacrolimus QD + MMF QD then MMF QD TARGET	LCP-tacrolimus QD + MMF QD then MMF QD	University Hospital, Limoges	marketed	Calcineurin inhibitor + antimetabolite immunosuppressant combination	Calcineurin (tacrolimus); inosine monophosphate dehydrogenase type II (MMF)
XR-tacrolimus QD + MMF BID	XR-tacrolimus QD + MMF BID	University Hospital, Limoges	marketed	Calcineurin inhibitor + Antimetabolite immunosuppressant combination	Calcineurin (tacrolimus); IMPDH type II (mycophenolate mofetil)
XR-tacrolimus QD + MMF BID then MMF QD	XR-tacrolimus QD + MMF BID then MMF QD	University Hospital, Limoges	marketed	Calcineurin inhibitor + Antimetabolite immunosuppressant combination	Calcineurin (tacrolimus); Inosine monophosphate dehydrogenase (mycophenolate mofetil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcineurin inhibitor + antimetabolite immunosuppressant combination class)

University Hospital, Limoges · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LCP-tacrolimus QD + MMF QD then MMF QD — Competitive Intelligence Brief. https://druglandscape.com/ci/lcp-tacrolimus-qd-mmf-qd-then-mmf-qd. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab